Ernexa Therapeutics, Inc. (ERNA)
4.30
+0.14
(+3.24%)
USD |
NASDAQ |
Sep 14, 10:48
Ernexa Therapeutics EPS Diluted (Quarterly) : -3.396 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.396 |
| March 31, 2026 | -6.952 |
| December 31, 2025 | -4.806 |
| September 30, 2025 | -3.768 |
| June 30, 2025 | -15.19 |
| March 31, 2025 | -0.1537 |
| December 31, 2024 | -42.09 |
| September 30, 2024 | -4.918 |
| June 30, 2024 | -1.024 |
| March 31, 2024 | -1.229 |
| December 31, 2023 | -1.139 |
| September 30, 2023 | -1.034 |
| June 30, 2023 | -0.8516 |
| March 31, 2023 | -1.056 |
| December 31, 2022 | -1.022 |
| September 30, 2022 | -2.488 |
| June 30, 2022 | -1.158 |
| March 31, 2022 | -3.496 |
| December 31, 2021 | -1147.65 |
| September 30, 2021 | -12760.12 |
| June 30, 2021 | -1783.28 |
| March 31, 2021 | -4997.10 |
| December 31, 2020 | -18247.80 |
| September 30, 2020 | -859.50 |
| June 30, 2020 | -867.30 |
| Date | Value |
|---|---|
| March 31, 2020 | -5269.95 |
| December 31, 2019 | -18.02 |
| September 30, 2019 | -4.885 |
| June 30, 2019 | -1.366 |
| March 31, 2019 | -4.368 |
| December 31, 2018 | 0.6144 |
| September 30, 2018 | 3.108 |
| June 30, 2018 | -2.00 |
| March 31, 2018 | -6.40 |
| December 31, 2017 | -4634.70 |
| September 30, 2017 | -2.80 |
| June 30, 2017 | -2.80 |
| March 31, 2017 | -1.60 |
| December 31, 2016 | -8.80 |
| September 30, 2016 | -12.40 |
| June 30, 2016 | -18.40 |
| March 31, 2016 | -20.00 |
| December 31, 2015 | -20.00 |
| September 30, 2015 | -20.00 |
| June 30, 2015 | -60.00 |
| March 31, 2015 | -40.00 |
| December 31, 2014 | -40.00 |
| September 30, 2014 | -20.00 |
| June 30, 2014 | -40.00 |
| March 31, 2014 | -20.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cerenome, Inc. | -1.305 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.009M |
| Total Expenses (Quarterly) | 4.009M |
| Enterprise Value | 0.1951M |
| Earnings Yield | -440.1% |
| Normalized Earnings Yield | -436.53 |